ArticleEndocrine oncology (Bristol, England)2022

Hypoparathyroidism: an uncommon adverse effect of treatment with durvalumab.

Alexander Kreze et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.